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Abstract
Background: Hypopituitarism in the elderly population is an underdiagnosed condition and may increase
comorbidities related to glucose metabolism, dyslipidemia, and cardiovascular risk factors. Optimization of hormone
replacement that considers alterations in clearance rates of hormones, interaction with other medications, and
evaluation of the risk-benefit ratio of treatment is a big challenge for clinical practice.
Objectives: This study aimed to evaluate classic cardiovascular risk factors in hypopituitary septuagenarians and
octagenarians by diagnosis and after long-term hormone replacement.
Methods: This is a retrospective observational study, with patients recruited and selected from a registry in a
tertiary medical center. We included patients aged 70–99 years with hypopituitarism, evaluated hormonal and
biochemical parameters, and cardiovascular risk scores were calculated by diagnosis and compared after long-term
follow-up. All patients gave informed consent. Patient data were compared to a sex and age-matched control
group, with long-term geriatric follow-up, without endocrine diseases.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: draluciananaves@gmail.com
4Endocrinology Unit, Faculty of Medicine, University of Brasilia, Brasilia, Brazil
Full list of author information is available at the end of the article
Rosa et al. Clinical Diabetes and Endocrinology             (2021) 7:6 
https://doi.org/10.1186/s40842-021-00119-6
(Continued from previous page)
Results: Thirty-five patients were included, 16 patients aged 70–75 years (72.61), 12 patients 76–80 years (72.28), 7
patients 81–99 years (89.28). Pituitary macroadenomas were the main cause of hypopituitarism, mean maximal
diameter 3.4 cm (2.9–4.3), and invasive craniopharyngiomas. At the moment of diagnosis, most patients were
overweight, and abdominal adiposity was observed in 76.9% of women and 36.4% of men, primarily in
octagenarians and nonagenarians. Comorbidities were frequent; 85.7% presented hypertension, 37.1% diabetes,
53.1% low HDL, 51.5% hypertriglyceridemia. Most patients presented more than two combined pituitary
deficiencies; hypogonadism in 88.6%, central hypothyroidism in 82.9%, GH deficiency in 65.7%, and adrenal
insufficiency in 25.7%. Analysis of cardiovascular risk prediction in the total cohort showed that 57.1% of patients
presented a reduction in the General Cardiovascular Disease (CVD) Risk Prediction Score and 45.7% in
atherosclerotic CVD risk estimated by ACC/AHA 2013 Pooled Cohort Equation, despite being submitted to
conventional hormone replacement, during the mean follow-up of 14.5 years. This reduction was not observed in
the control group.
Discussion and conclusion: In this study, aged hypopituitary patients presented a reduction in estimated general
CVD risk during long-term follow-up, despite replacement with corticosteroids, levothyroxine, or gonadal steroids.
Early diagnosis and treatment of hypopituitarism in the elderly remain challenging. Larger studies should be
performed to assess the risk-benefit ratio of hormone replacement on the metabolic profile in septuagenarian and
octogenarian patients.
Background
Hypopituitarism in the elderly is a misdiagnosed and
underestimated condition, with targeted hormonal re-
placement mandatory to minimize metabolic and sys-
temic complications. A Spanish population-based study
evaluated the prevalence (45.5 cases per 100,000) and in-
cidence (4,2 cases per 100,000) of pituitary deficiencies
in the adult population from 18 to 79 years [1]. However,
this study’s median age was 50 years, and epidemio-
logical data in older patients is lacking.
The effects of aging on the endocrine system involve
impairment of signaling mechanisms, biorhythms, and
target sensitivity, and represent physiological adaptations
of senescence [2]. However, hypopituitarism is a life-
threatening condition that should not be neglected and
needs to be recognized [3].
Clinical presentation is often insidious, and symptoms
are generally nonspecific, including weakness, fatigue,
lethargy, general discomfort, loss of appetite and weight,
hyponatremia, and varying according to the severity of
deficient hormones. Unfortunately, delays in diagnosis
may be due to the symptoms being ascribed to aging per
se or associated comorbidities [4].
In most cases, the symptoms are related to the under-
lying cause. In adult-acquired hypopituitarism, the lead-
ing etiological causes are pituitary tumors with supra or
para-sellar extensions or their treatment effects [4].
The incidence of Pituitary Adenomas (PA) increases
with age, being present in 15% of autopsies in octogenar-
ians [5]. Non-Functioning Pituitary Macroadenomas are
the most frequent in aged patients, probably as a conse-
quence of the disease’s long duration before appropriate
diagnosis. Aggressive Pituitary Tumors in the elderly
may appear clinically similar to younger adults, but
present challenges for their best management when con-
sidering the presence of other comorbidities [6, 7].
These lesions can produce defects in the visual field,
as bitemporal hemianopsia due to the compression of
the optic chiasma, or diplopia related to the invasion of
the cavernous sinus and the cranial pair’s involvement.
Other symptoms associated with tumor growth and local
invasion are headaches and rhinoliquorrhea due to CSF
fistula [8, 9].
Considering the rise in life expectancy and the im-
provement in endoscopic endonasal transsphenoidal sur-
gery, more individuals aged > 65 have been submitted to
surgery to benefit from debulking procedures. In a re-
cent study, the authors noted that elderly patients are
more vulnerable to postoperative complications such as
fluid and electrolyte imbalance and stroke risk due to
their decreased vascular adaptability [10]. The extent of
resection has a significant impact on postoperative hypo-
pituitarism [10].
Hypopituitarism involves multiple endocrine axes, and
metabolic effects are diverse and systemic. Growth Hor-
mone (GH) deficiency in adults contributes to muscle
weakness and decreased bone mass, leading to frequent
falls and fractures, increased complications, and mortal-
ity [11]. It is known to be associated with an unfavorable
lipid profile, with increased triglycerides, cholesterol,
body fat, and liver steatosis, all of which are associated
with an increased incidence of vascular disease [12].
A recent study demonstrated that hypopituitary pa-
tients without GH replacement have more dyslipidemia,
but lower homeostasis model assessment (HOMA-IR)
and waist/height values, and the occurrence of metabolic
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syndrome were similar to a control group, paired by age,
gender, and Body Mass Index (BMI) [13].
This observation can be supported by the findings de-
scribed in Itabaianinha County, in the Brazilian state of
Sergipe, where 105 study subjects have severe isolated
GH deficiency due to a homozygous inactivating muta-
tion in the GH releasing hormone (GHRH) receptor
(GHRHR) gene [14]. The authors hypothesized an IGF-I
dual action, either promoting (by increasing proliferation
of vascular smooth muscle cells), or preventing (by in-
creasing nitric oxide formation, vascular compliance,
and insulin sensitivity) atherogenesis. Persistent very low
IGF-I levels might have a protective role, whereas a
milder decrease may be noxious [15].
The mitogenic and anti-apoptotic role of IGF-1 is a
subject of interest and some authors have associated
tumor regrowth to GH replacement. Safety and Appro-
priateness of Growth Hormone Treatments in Europe
(SAGhE), a recent, large cross-European cohort study,
described very high relative risk of meningioma after
GH replacement in patients whose initial diagnoses were
central nervous system (CNS) tumor with previous
radiotherapy [16]. These controversial issues must be
taken into account when making decisions to replace
GH in elderly patients.
Clinical manifestations of Secondary Adrenal Insuf-
ficiency are nonspecific, such as lassitude in the early
stage, with symptoms frequently attributed to disabil-
ity related to aging. This is an important diagnosis in
the elderly and has a significant impact on the im-
mune system, increasing the risk of infections, which
could increase complications [11]. Severe hyponatre-
mia may be a revealing sign of hypopituitarism after
60 years of age, and its recognition is critical to redu-
cing hospital stay and mortality [4, 17, 18]. On the
other hand, inadequate steroid replacement may in-
crease comorbidities in glucose metabolism and
dyslipidemia, exacerbating both cardiovascular disease
and metabolic syndrome [19, 20].
The androgen replacement in older patients is contro-
versial. Some studies have suggested a protective effect
of testosterone therapy against cardiovascular (CV)
events in older men [18]. Others have shown a higher
risk of myocardial infarction [21, 22]. A recent review
has highlighted the main effects of testosterone on the
cardiovascular system, with favorable effects on vasomo-
tion, arterial stiffness, cardiac electrophysiology, con-
tractility, and remodeling [23].
Some authors have suggested an association between
mortality and hypopituitarism than expected for age and
sex-matched control population [20, 24, 25]. Recogniz-
ing manifestations of endocrine diseases in older patients
is essential in the management approach of geriatric pa-
tients. Aging leads to considerable physiological changes
in renal function, nutritional aspects and may change
hormone transport, clearance, and action in older pa-
tients [2]. Careful monitoring is essential to achieve
therapeutic benefits and minimize the adverse effects of
hormone therapy (Fig. 1). As life expectancy increases,
elderly individuals become candidates for primary and
secondary prevention of cardiovascular disease [26, 27].
The aim of this study is to analyze the association be-
tween hormone deficiencies, long-term hormone re-
placement, and classic cardiovascular risk factors and
estimated cardiovascular disease risk during first visit,
and recent clinical evaluation, in a sample of septuage-
narians, octagenarians, and nonagenarians patients in
the long term follow-up.
Objective
To identify classic cardiovascular and metabolic risk fac-
tors in over 70 years old patients during the treatment
of hypopituitarism in long term follow-up.
Fig. 1 Potential mechanisms and therapeutic benefits of hormone replacement in elderly hypopituitary patients
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Subjects and methods
This is a transversal observational study of classic car-
diovascular risk factors in aged patients with a con-
firmed diagnosis of hypopituitarism, compared to the
retrospective analysis of the same parameters collected
in the moment of diagnosis from the electronic registry.
Individuals were recruited and data were gathered from
August 2019 to April 2020 at the Neuroendocrinology
Unit of the University Hospital of Brasília, considered a
Pituitary Center of Excellence. The data concerning
hypopituitary patients were compared to a sex and age-
matched control group without a diagnosis of endocrine
diseases or acute cardiac dysfunction, some of them re-
cruited from a geriatric cohort from a private clinic and
others from the University Hospital of Brasília (HUB).
Barriers and local clinical protocols
In our center, patients with adult onset GH deficiency
(AODGH) older than 60 years, do not receive GH re-
placement, regarding some local policies: (1) lack of re-
imbursement; (2) restrictions on providing the drug in
hospital pharmacies for this group of patients; (3) thera-
peutic guidelines that recommend avoiding GH treat-
ment in patients with voluminous tumors, intracranial
hypertension and retinopathy. Women with secondary
hypogonadism are treated with estrogens and progester-
one on personalized regimens until a maximum age of
60 years old. Testosterone replacement is prescribed for
men until 75 years old, but should be adjusted or discon-
tinued in presence of polycytemia, thrombosis or acute
cardiovascular events. Bone densitometry with evalu-
ation of body composition is performed every 3 years as
a routine evaluation in our geriatric clinic.
Inclusion and exclusion criteria
Patients included in the study were over 70 years of age,
with periodical clinical follow-ups, presenting the follow-
ing criteria: (i) confirmed diagnosis of hypopituitarism,
including two or multiple hormone deficiencies
(MPHD), and (ii) patients with thyrotrophic and adreno-
corticotrophic deficiencies with adjusted replacement
doses of levothyroxine and glucocorticoids. Exclusion
criteria were: (i) patients with active functioning pituit-
ary tumors (Cushing’s disease, prolactinoma, acromeg-
aly), (ii) chronic use of supraphysiological doses of
corticoids or levothyroxine, (iii) use of cabergoline,
bromocriptine, or somatostatin analogs during the long-
term follow-up.
Control group
The control group was composed of consecutive pa-
tients, regularly evaluated in a geriatric clinic, most of
them from the Geriatric Service of Brasilia University
Hospital, and enrolled in regular clinical follow-up since
2006. Initially, we selected 128 patients 70 years and
older, with no history of hypopituitarism.
Thirty-eight subjects were excluded from the original
sample. The exclusion criteria for the control group
were: history of ischemic heart disease (n = 20) or ische-
mic stroke (n = 7) and subjects with missing information
(n = 6). All patients had their first medical evaluation at
our hospital at least 10 years before the inclusion in the
study. The mean time of follow-up was 13.8 years. We
have included 90 patients > 70 years old, matched on
age, body mass index (BMI) and sex with the hypopituit-
ary patients.
Clinical and laboratory evaluation
Clinical evaluation of study participants comprised
weight, height, waist, and Blood Pressure (BP) measure-
ments (mean of three independent measurements), at
the moment of the last follow-up medical evaluation. All
patients were submitted to Magnetic Resonance Imaging
(MRI) of the sellar region to determine the etiology of
hypopituitarism. Blood samples were drawn in the
morning after overnight fast and hormonal evaluation,
including GH, prolactin, IGF-1, cortisol, FSH, LH, Tes-
tosterone or estradiol, TSH, fT4. Peptides were deter-
mined by chemiluminescent immunometric assay
(Immulite 2000). A solid-phase enzyme-labeled chemilu-
minescent immunometric assay was used to measure
serum IGF-I with the sample pretreatment on an on-
board dilution step (Immulite 2000). Lipids and glucose
serum measurements were determined respectively by
hexokinase and IFCC without pyridoxal phosphate and
compared to the same parameters by the diagnosis of
hypopituitarism.
The criteria for the diagnosis of hypopituitarism were
based on the Endocrine Society Clinical Practice Guide-
line [17]. Adrenal insufficiency was considered when
basal cortisol levels ≤ 3 μg/dL, or in Insulin Tolerance
Test (ITT), cortisol ≤ 18 μg/dL; GH deficiency when GH
peak on ITT ≤ 3 ng/mL or IGF-1 lower than age-
matched reference values; prolactin deficiency if lower
than reference values; thyrotropic deficiency if fT4 < 0.8
ng/dL and low or inappropriate TSH levels.
The therapeutic regimens of pituitary deficiencies
were: (i) Prednisone administered once daily in the
morning, in doses ranging from 2.5–5 mg per day, be-
cause commercial manufacture formulations of hydro-
cortisone acetate are not available in Brazil; (ii)
Levothyroxin administered in doses from 1.4–1.6 μg/kg/
day; (iii) Intramuscular formulations containing testos-
terone enanthate or cypionate administered every 2 to 3
weeks. No women had estrogen therapy. No patient was
submitted to GH replacement. Patients were evaluated
every 4 months, and hemogram, glucose, lipid profile,
fT4, Testosterone, PSA, hepatic and renal functions were
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measured. All patients were treated for comorbidities ac-
cording to validated guidelines.
Cardiovascular disease risk estimation
For each patient, the cardiovascular disease risk was esti-
mated via two widely utilized risk scores with data from
the period of diagnosis and the last clinical meeting.
Each patient was evaluated by the same team from the
Unit of Endocrinology from University Hospital of Bra-
sília (HUB).
One of the scores adopted was the 10-year General
Cardiovascular Disease (CVD) Risk Prediction Score
Using Lipids published by the Framingham Heart Study
[24]. The considered parameters were age, diabetes,
smoking, treated and untreated systolic blood pressure,
total cholesterol, HDL cholesterol. The 10-year CVD risk
is considered low < 10%, moderate 10–20% and high>
20%. The score provides a 10-year risk prediction of the
following CVDs: coronary death, myocardial infarction,
coronary insufficiency, angina, ischemic stroke,
hemorrhagic stroke, transient ischemic attack, peripheral
artery disease, and heart failure.
The atherosclerotic cardiovascular disease (ASCVD)
was estimated using the calculator provided by the ACC
/ AHA Guideline on the Assessment of Cardiovascular
Risk in 2013 based on the Pooled Cohort Equations (25).
The equation estimates a 10-year risk of coronary death
or nonfatal myocardial infarction or fatal or nonfatal
stroke [25]. Both calculators were derived from cohorts
without previous atherosclerotic cardiovascular disease.
To adapt and standardize the age range of our popula-
tion, which goes beyond the age allowed by the scores,
we used the age of 79 years (maximum age established
by the scores) to calculate the patients’ risks. The same
scores were calculated for a control group age and sex-
matched.
Statistical analysis
Data were analyzed using the IBM SPSS Statistics ver-
sion 20.0 software (IBM Corp. released in 2011. IBM
SPSS Statistics for Mac, Version 20.0. Armonk, NY: IBM
Corp). Categorical variables are summarized as number
and percentage, whereas numeric variables are summa-
rized as mean ± standard deviation (SD) and median
(min-max) where appropriate. Categorical variables were
compared using the Chi-square test. In the comparison
of numerical variables between the groups, one-way ana-
lysis of variance (ANOVA) was used when assumptions
were met, and the Kruskal–Wallis test was used when
assumptions were not met. Covariance analysis
(ANCOVA) was done to compare the difference be-
tween Framingham Risk Score (FRS) at diagnosis and at
the last clinical meeting for each patient, considering
time’s follow-up as a covariate. A p-value < 0.05 was
considered to be statistically significant.
Ethics approval
The study complied with the WMA Declaration of
Helsinki and its amended versions of ethical principles
for medical research involving human subjects. It was
approved by the Ethical Committee on Human Subject
Research from the Faculty of Health Sciences, University
of Brasilia. All patients signed a proper informed consent
before participating in the study.
Results
Sample of patients with hypopituitarism
From a cohort of 104 patients aged more than 70 years
with previously reported pituitary dysfunction in our
hospital (incidental findings of intrasellar, parasellar, and
suprasellar lesions, clinical investigation of hypopituitar-
ism), 35 patients matched the inclusion criteria: 16 pa-
tients aged 70–74 years (72.61 years, 70–74), 12 patients
75–80 years (77.28 years, 75–78), seven patients 81–99
years (89.28 years, 81–99). Of the 69 patients that did
not match the inclusion criteria, 48 (69.5%) presented
functioning tumors and were on medical treatment with
somatostatin analogs or dopamine agonists, and 21 (30,
4%) reported periods of inappropriate use of supraphy-
siological doses of glucocorticoids, related to clinical
conditions as hyponatremia, acute infections or inflam-
matory osteo-articular comorbidities.
The mean follow-up since diagnosis of hypopituitarism
in our clinic was 14.8 (6–18) years. As an underlying
cause of hypopituitarism, most patients had pituitary
macroadenomas, mean maximal diameter 3.4 cm (2.9–
4.3). Craniopharyngiomas with supra, and parasellar ex-
tension were also observed (Table 1).
Some patients were submitted to surgery and adjuvant
radiotherapy, while 20% of patients from 70 to 74 years
presented previous apoplexy. Few patients were previ-
ously treated with bromocriptine, cabergoline, or octreo-
tide before the diagnosis of hypopituitarism (Table 1).
All patients with a diagnosis of functioning pituitary tu-
mors matched the criteria of cure for hormone hyperse-
cretion before inclusion in the study.
Hypopituitarism was present in all patients by diagno-
sis. GH deficiency was observed in 65.7% of patients,
hypogonadism in 88.6%, central hypothyroidism in
82.9%, and adrenal insufficiency in 25.7%. 94.28% of pa-
tients presented more than two combined deficiencies.
At clinical evaluation by the time of the diagnosis of
hypopituitarism, most of the patients were overweight,
with 25.71% considered obese. Relative sarcopenia was
observed in all patients. Abdominal adiposity was
present in 76.92% of women and 39.13% of men, and
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was more frequent in octagenarians and nonagenarians
(Table 2).
Comorbidities were frequent by diagnosis. 85.71%
presented hypertension, 37.14% diabetes, 62.8% hyper-
cholesterolemia, and 48.57% hypertriglyceridemia. All
patients were treated for comorbidities according to
validated guidelines and achieved control after 3
months of medical treatment. (Table 3).
Control group
The control group was composed of consecutive pa-
tients, regularly evaluated in a geriatric clinic, most of
them from the Geriatric Service of Brasilia University
Hospital, and enrolled in regular clinical follow-up. Ini-
tially, we selected 128 patients 70 years and older, with
no history of hypopituitarism.
We excluded 38 subjects from the original sample.
The exclusion criteria for the control group were: history
of ischemic heart disease (n = 20) or ischemic stroke
(n = 7) and subjects with missing information (n = 6). All
patients had their first medical evaluation at our hospital
at least 10 years before the inclusion in the study. We
have included 90 patients > 70 years old, matched on
age, body mass index (BMI) and sex with the hypopituit-
ary patients.
The sample was composed of 40 patients 70–74
years, 31 patients 75–80 years, and 19 patients 80–99
years. The mean time of regular medical follow-up
was 13.8 years, between the first evaluation and the
inclusion in this study. Comorbidities at first evalu-
ation were hypertension (78.1% of patients), diabetes
(35.2%), hypercholesterolemia (60.1%), and hypertri-
glyceridemia (35.8%). All control subjects included
Table 1 Pituitary dysfunctions and treatment by diagnosis







Mean age (years) 72.1 ± 1.2 76.3 ± 1.3 89.2 ± 7.0 0.01
Microadenomas (%) 18.8 16.7 0 0.47
Macroadenomas (%) 81.2 83.3 100.0 0.47
NFPA (%)a 37.5 50.0 71.4 0.40
Prolactinomas (%) 12.5 25.0 28.6
Acromegaly (%) 31.2 16.7 0
Craniopharingiomas (%) 18.8 8.3 0
Diameter of PA at diagnosis (mm) 22.6 ± 10 26.0 ± 10 25.1 ± 8 0.66
Surgery(%) 43.8 58.3 14.3 0.17
Radiotherapy (%) 12.5 25.0 14.3 0.66
aNFPA (non functionning pituitary adenomas)
Table 2 Clinical characteristics of patients by diagnosis










< 25 (%) 34.3 50.0 33.3 0
≥25 and < 30 (%) 57.1 43.8 66.7 71.4 0.06
≥30 (%) 8.6 6.2 0 28.6
Waist (cm)
➢ 88 women (%) 76.9 62.5 100.0 100.0 0.29
➢ 102 men (%) 36.4 50.0 18.2 66.7 0.18
88 women OR 102 men (%) 51.4 56.2 25.0 85.7 0.03
SBP(mmHg)a 130 130 136 122 0.45
DBP(mmHg)b 79 83 77 75 0.31
a (SBP) Systolic Blood Pressure
b (DBP) Dyastolic Blood Pressure
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were conventionally treated by anti-hypertensives and
hypolipemiant drugs.
ASCVD algorithm applied by the ACC / AHA
All patients had high cardiovascular risk scores by diag-
nosis, but at follow-up 57.14% of patients presented a re-
duction in estimated 10-year CVD risk of 14.57 years.
When broken down by age group, calculated 10-year
CVD risk reduced 66% in the 70–75 group, 57.15% in
the 76–80 group, and 42.85% in the 81–99 group, during
the long-term follow-up (p < 0.003). No significant re-
duction in estimated 10-year ASCVD risk was observed
(Table 4).
The frequency of comorbidities and estimated cardio-
vascular risk scores at diagnosis was compared in con-
trol and hypopituitary groups (Table 5).
There was no significant statistical difference in rela-
tion to Framingham score at current evaluation (p =
0.341) or at the time of diagnosis (p = 0.721) between
GH deficient and GH non-deficient patients. Similar ob-
servation was obtained to the coronary calcium score.
Non-significant differences between the two groups were
realized either at current time (p = 0.548) or the time of
diagnosis (p = 0.564).
Comparing the hypopituitary patients to the control
group, most of the non-hypopituitarism geriatric pa-
tients presented an increase in estimated 10-year CVD
risk (p < 0.001) and also in 10-year ASCVD risk (p <
0.001) (Fig. 2).
No patient from our cohort presented acute cardiovas-
cular events in 14.8 years follow-up. In the control
group, only one patient, aged 78, presented thrombosis,
related to a long trip, and solved after conventional anti-
coagulant treatment.
Discussion
The diagnosis of hypopituitarism in elderly patients
has many challenges. The presence of clinical comor-
bidities prevalent in aging may raise concerns about
possible complications of replacement with thyroid
hormones, glucocorticoids, and sex steroids.
Optimization of the individual hormone dosage and
long-term monitoring remain a primary clinical goal
in hypopituitary patients [26].
In this study, the presence of multiple pituitary axis in-
volvements in patients over 70 was a relevant finding.
The most frequently compromised axes were the go-
nadotropic, somatotrophic, and thyrotrophic, followed
by the adrenocorticotrophic. The main symptoms were
related to muscle weakness and fatigue, present among
Table 3 Co-morbidities in Hypopituitary patients









Hypertensiona (%) 85.7 93.8 83.3 71.4 0.35
Diabetesb (%) 37.1 43.8 33.3 28.5 0.74
HDL < 40 men/ HDL < 50 women 53.1 64.3 50 33.3 0.42
Hypertrigliceridemia > 150mg/dL (%) 51.5 57.1 58.3 28.5 0.39
Hypopituitarism (%)
GH deficiency 65.71 56.2 66.7 85.7 0.39
Hypogonadism 88.6 87.5 83.3 100 0.53
Hypothyroidism 82.9 87.5 83.3 71.4 0.64
Adrenal Insufficiency 25.7 12.5 33.3 42.9 0.23
Multiple Pituitary Hormone Deficiencies (MPHD) 0.52
2 axes 45.7 50 41.7 42.9
3 axes 28.6 37.5 25 14.3
4 axes 20 6.2 25 42.9
aMost patients treated by enalapril and valsartan
b Patients treated by diet, metformin and/or glibenclamide
Table 4 Metabolic Parameters and classic cardiovascular risk




Body Mass Index (kg/m2) 27.6 ± 4.32 26.8 ± 3.83 0.649
Waist (cm) 102.5 ± 10.09 99.4 ± 10.36 0.004
HDL cholesterol (mg/dL) 46.8 ± 13.27 49.3 ± 11.98 0.159
LDL cholesterol (mg/dL) 112.8 ± 33.67 87.7 ± 28.43 0.000
Triglycerides 167.2 ± 97.18 125.7 ± 38.93 0.023
Fasting Glucose (mg/dL) 116.3 ± 62.58 103.3 ± 28.43 0.137
Framinghan Score 31.7 ± 20.23 26.3 ± 14.07 0.003
Calcium Score 41.6 ± 15.6 42.3 ± 14.12 0.20
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patients’ longterm complaints and attributed, in other
medical evaluations, to physical and psychological de-
terioration related to aging.
In our cohort, all patients were aged > 70 years, and
hormonal replacement must be carefully analyzed for
risks and benefits. Growth hormone deficiency was not
replaced, due to several reasons, such as the lack of re-
imbursement and the imbalance of potential risks re-
lated to some comorbidities, as hypertension (85.7%)
and diabetes (37.1%) with some degree of retinopathy.
Most patients presented voluminous tumors and some
were treated previously by radiotherapy. A recent paper
from the European Society of Endocrinology has identi-
fied and described some country-specific differences in
the management of AGHD patients, regarding local pol-
icies and protocols [27].
The comparison between patients with GH defi-
ciency, to control group or age matched hypopituitary
patients with normal somatotropic function, have
shown no significant statistical difference in relation
to Framingham score nor to the coronary calcium
score at the two points of analysis. This data suggest
that despite the lack of GH replacement, there was
no influence on the cardiovascular risk factors
assessed in this study.
Hypogonadism was frequent, and gender differences
were observed concerning steroid replacement. All
women included in this study were at least
septuagenarians at baseline and none of them reported
previous menopause replacement therapy.
A recent metanalysis suggested an increased risk of
stroke in older women, related to underlying disease and
timing of initiation of hormonal replacement [28].
Most of the men included in the study received intra-
muscular formulations containing testosterone
enanthate or cypionate that were administered every 2
to 3 weeks. No difference was found on estimated car-
diovascular risk scores between genders.
Most of the patients were overweight, with abdominal
obesity more frequent in older women. Studies suggest
that elderly patients are more prone to malnutrition
when clinical and biochemical parameters are analyzed,
increasing morbidity and mortality. The Body Mass
Index (BMI) represents low reliability since the increase
in adiposity associated with sarcopenia may reflect a
normal BMI [27].
Atherogenesis results from genetic predisposition
and exposure to risk factors, such as dyslipidemia,
diabetes, sedentary behavior, smoking, hypertension,
and emotional stress. Longevity may represent indi-
viduals who have manifested less cardiovascular risk
factors during their lifetime. In individuals over 80
years old, the pathogenic puzzle is uncertain, and data
is scarce. Some authors have suggested new modula-
tors for atherogenesis as cellular senescence, syn-
drome of frailty, sarcopenia [23, 28].
Table 5 Comparative data on co-morbidities in Control Group and Hypopituitary patients at baseline
Control Group (%) Hypopituitary Patients (%) P value
Diabetes 35.2 37.1 0.74
Hypertension 78.1 85.7 0.48
Hypercholesterolemia 60.1 62.8 0.35
Hypertriglyceridemia 35.8 48.57 0.07
Framinghan Score 19.8 ± 7.6 31.7 ± 20.23 0.01
Estimated Calcium Scorea 18.6 ± 8.1 41.6 ± 15.6 0.01
aASCVD applied by the ACC / AHA
Fig. 2 Cardiovascular Risk Scores before, and after long term hormonal replacement in elderly hypopituitary patients
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Sarcopenia is a relevant component of senescence and
frailty syndrome and may increase the atherogenic
process due to the replacement of muscle mass by adi-
pose tissue. This metabolic pathway is an essential player
in cardiometabolic health in hypopituitary patients, as
the changes in body composition are related to growth
hormone deficiency and hypogonadism [29–31]. Some
authors have described that sarcopenia has more impact
than weight excess in subclinical atherosclerosis in octa-
genarians [32].
In our study, very elderly patients presented abdominal
fat accumulation, and most of the septuagenarians and
octagenarians were considered overweight or obese. In
hypopituitarism, trophic hormones for muscle synthesis
are insufficient, and adipose tissue gradually replaces
muscle tissue and accumulates in the abdominal visceral
region. Most of the patients from our cohort presented
GH deficiency, but none were submitted to growth hor-
mone replacement.
All hypocortisolemic patients were treated on exogen-
ous standard steroid substitution, which fails to mimic
the natural circadian rhythm of cortisol secretion per-
fectly. Inadequate steroid replacement results in risk ex-
acerbation of both cardiovascular disease and metabolic
syndrome [17, 33].
Hormonal deficiencies can contribute to the wors-
ening of long-term risk factors. Some authors suggest
that elderly patients with adrenal insufficiency present
a sarcopenia tendency, despite being classified as
overweight or obese by the BMI. Long-term replace-
ment with glucocorticoids, along with the aging
process, has a significant impact on changes in body
composition, especially in the redistribution of body
fat [34]. On the cardiovascular system, glucocorticoids
enhance vascular reactivity to angiotensin II and nor-
epinephrine through the expression of α1B and β2 re-
ceptors, the induction of Ca2+ voltage-dependent
channels in vascular smooth muscle cells, and the in-
duction of Na/K-adenosine triphosphatase (ATPase)
in cardiomyocytes [35]. Thus, inadequate glucocortic-
oid replacement could worsen hypertension.
In our study, despite high waist diameter, steroid re-
placement did not increase classic cardiovascular risk
factors. This finding is in accordance with other authors
that did not find an increase in adipocytokines in pa-
tients with adrenal insufficiency under corticotherapy
[36]. However, recent studies suggested that testosterone
treatment of older men was associated with progression
of noncalcified atherosclerotic plaque [37]. Most of our
patients had a previous diagnosis of hypertension and
dyslipidemia, treated conventionally during long term
follow-up. No patient from our cohort, nor from the
control group, presented acute cardiovascular events in
14.8 years of follow-up.
The estimated CVD risk was high in all hypopituit-
ary patients at the time of inclusion in the study.
Throughout follow-up, there was a a significant re-
duction in estimated CVD risk amongst most pa-
tients, with the chronically administered hormonal
replacement having no negative impact. This finding
was not observed in the age-matched control group.
It is hard to accurately estimate CVD risk in very eld-
erly subjects as these populations were underrepre-
sented in the cohorts from which the risk scores are
derived from [38]. However, it is remarkable that
using a standard reference age in the risk scores, the
other metabolic variables changed favorably after
years of follow-up of hypopituitary patients.
In our series, an increase in abdominal adiposity in
older women and the presence of Metabolic Syndrome
were frequent, in addition to an elevated estimated gen-
eral CVD and ASCVD by the risk scores at the time of
inclusion in the study. Thus, it should be noted that
other cardiovascular risk factors not included in the risk
scores such as Metabolic Syndrome and Sarcopenia
should be considered in the clinical evaluation and re-
quire close monitoring to prevent coronary disease dur-
ing aging [39, 40].
The use of cardiovascular risk scores in the elderly, es-
pecially in those 70 years and older, has limited value
due to a lack of representation of this population in the
cohorts used to create both Framingham and ACC/AHA
Pooled Cohort Equation [38]. As a limitation, we had to
standardize the age of our population to the maximum
age allowed in the calculators, 79 years. A cardiovascular
risk calculator specifically designed for the very elderly is
not yet available, therefore in clinical practice the scores
used in this study are still used. Furthermore, competing
health problems, the presence of frailty and multimor-
bidity challenge the use of traditional cardiovascular risk
scores in older adults. However, some recent studies
suggest that the overall ASCVD prediction by the pooled
cohort equations was good at least in adults aged ≥65
years [41, 42].
We recognize that a significant limitation of the study
is the sample size. However, the underdiagnosis of hypo-
pituitarism in this age group makes our findings relevant
and reinforces the relevance of its recognition and
optimization of hormone replacement. Another limita-
tion of our study is the lack of adequate cardiovascular
risk calculators for the very elderly population, which
motivated us to adapt tools better validated in younger
populations. Although it turns our risk prediction unpre-
cise, real-world clinical practice faces the same chal-
lenge. However, it is remarkable that using a standard
reference age in the risk scores, the other metabolic vari-
ables changed favorably after years of follow-up of hypo-
pituitary patients.
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Conclusion
In this study, aged hypopituitary patients presented a re-
duction in estimated CVD risk during long-term follow-
up, despite hormone replacement with low-dose gluco-
corticoids, levothyroxine, or androgens in men. Neither
the hypopituitarism group nor controls had any cardio-
vascular events during the long-term follow-up.
Hormone replacement had no negative impact on car-
diovascular and metabolic risk scores in septuagenarian,
octogenarian, and nonagenarian hypopituitary patients.
Considering the relevance of early diagnosis and the lack
of data on medical literature, more extensive studies
should be performed to assess the benefit of hormone
replacement in metabolic control in older hypopituitary
patients.
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